Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Related Keywords

Ohio ,United States ,Cleveland ,Afshin Dowlati ,Roberth Gries ,Thoracic Scientific Team At University Hospitals ,Jazz Pharmaceuticals ,Cancer Drug Development At University Hospitals ,Department Of Medicine Division Hematology ,School Of Medicine ,Gilead Sciences ,Astrazeneca ,Cleveland Medical Center ,Medicine Division ,Developmental Therapeutics Program ,Case Comprehensive Cancer Center ,Endowed Director ,Cancer Drug Development ,University Hospitals ,Thoracic Oncology Program ,University Hospitals Seidman Cancer Center ,Lung Cancer ,Thoracic Scientific Team ,Cleveland Medical ,Sacituzumab Govitecan ,Antibody Drug Conjugate ,Trodelvy ,Esmo Congress ,Tropics 03 Trial ,D ,Extensive Stage Small Cell Lung Cancer ,Es Sclc ,Nsclc ,Small Cell Lung Cancer ,